Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report

ConclusionsEscitalopram monotherapy in acute MDD did not result in significant cognitive improvements. We provide novel evidence that escitalopram continuation in responders does not adversely affect cognition, but adjunctive aripiprazole in escitalopram non-responders worsens reaction time. Treatments targeting cognitive dysfunction are needed in MDD.ClinicalTrials.gov identifierNCT01655706; 2 August, 2012.

http://link.springer.com/10.1007/s40263-021-00793-1

Source: CNS Drugs - March 8, 2021 Category: Neurology Source Type: research